odalasvir + AL-335 + simeprevir

A fixed-dose **oral combination of three direct-acting antiviral agents**—the NS5A inhibitor odalasvir, the uridine nucleotide analog prodrug polymerase inhibitor AL-335 (also called adafosbuvir), and the NS3/4A protease inhibitor simeprevir—investigated for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotypes 1, 2, 4, 5, and 6. The combination demonstrated high sustained virologic response rates (SVR12 and SVR24 ≥97%) and was well-tolerated in Phase 2 trials in non-cirrhotic and cirrhotic, treatment-naive and experienced patients. Each component targets a different viral protein: odalasvir inhibits HCV NS5A, AL-335 is metabolized to an active nucleoside disrupting HCV NS5B polymerase, and simeprevir blocks HCV NS3/4A protease activity[1][2][3][4][6][7][8].

Brand names

JNJ-4178JNJ4178JNJ 4178

Other names

adafosbuvir + odalasvir + simeprevirJNJ-4178JNJ4178JNJ 4178